Description: Annexin Pharmaceuticals AB (publ), a biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. The company develops ANXV, a human recombinant protein. It offers Annexin A5 to protect and repair blood vessels and counteract inflammation. The company was founded in 2014 and is based in Stockholm, Sweden.
Home Page: www.annexinpharma.com/sv
Drottninggatan 65
Stockholm,
111 36
Sweden
Phone:
46 7 09 65 16 65
Officers
| Name | Title |
|---|---|
| Dr. Anders Haegerstrand M.D., Ph.D. | Chief Exec. Officer |
| Mr. Henrik Palm | Chief Financial Officer |
| Ms. Susan Suchdev | Chief Operating Officer |
| Dr. Anna Frostegård M.D., Ph.D. | Chief Scientific & Medical Officer |
| Ulrika Harndahl | Head of CMC |
| Dr. Mario Fsadni L.L.M., M.Sc. | Therapy Area Head of Ophthalmology |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.9048 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |